MX2022001690A - Compuestos deuterados para usarse en el tratamiento del cancer. - Google Patents

Compuestos deuterados para usarse en el tratamiento del cancer.

Info

Publication number
MX2022001690A
MX2022001690A MX2022001690A MX2022001690A MX2022001690A MX 2022001690 A MX2022001690 A MX 2022001690A MX 2022001690 A MX2022001690 A MX 2022001690A MX 2022001690 A MX2022001690 A MX 2022001690A MX 2022001690 A MX2022001690 A MX 2022001690A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
deuterated compounds
deuterated
derivatives
Prior art date
Application number
MX2022001690A
Other languages
English (en)
Inventor
Robert Heald
Martin Stockley
Harry Finch
Peter Blencowe
Mark Charles
Tennyson Ekwuru
Hollie Mccarron
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2019/052240 external-priority patent/WO2021028643A1/en
Priority claimed from GBGB1917863.1A external-priority patent/GB201917863D0/en
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Publication of MX2022001690A publication Critical patent/MX2022001690A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La solicitud se relaciona con derivados de amida deuterados de la fórmula (I) y su uso en el tratamiento y profilaxis del cáncer, y con composiciones que contienen dichos derivados y procesos para su preparación. (ver Fórmula).
MX2022001690A 2019-08-09 2020-08-10 Compuestos deuterados para usarse en el tratamiento del cancer. MX2022001690A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2019/052240 WO2021028643A1 (en) 2019-08-09 2019-08-09 Heterocyclic compounds for use in the treatment of cancer
GBGB1917863.1A GB201917863D0 (en) 2019-12-06 2019-12-06 Novel compounds
PCT/GB2020/051901 WO2021028670A1 (en) 2019-08-09 2020-08-10 Deuterated compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022001690A true MX2022001690A (es) 2022-05-10

Family

ID=72039615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001690A MX2022001690A (es) 2019-08-09 2020-08-10 Compuestos deuterados para usarse en el tratamiento del cancer.

Country Status (23)

Country Link
US (1) US20220259174A1 (es)
EP (1) EP4010329B9 (es)
JP (1) JP2022544211A (es)
KR (1) KR20220050148A (es)
CN (1) CN114846003A (es)
AU (1) AU2020327661A1 (es)
BR (1) BR112022002496A2 (es)
CA (1) CA3149119A1 (es)
DK (1) DK4010329T3 (es)
ES (1) ES2952281T3 (es)
FI (1) FI4010329T3 (es)
HR (1) HRP20231037T1 (es)
HU (1) HUE063145T2 (es)
IL (1) IL290415A (es)
LT (1) LT4010329T (es)
MX (1) MX2022001690A (es)
PL (1) PL4010329T3 (es)
PT (1) PT4010329T (es)
RS (1) RS64486B1 (es)
SI (1) SI4010329T1 (es)
TW (1) TW202120486A (es)
WO (1) WO2021028670A1 (es)
ZA (1) ZA202201364B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024507725A (ja) * 2021-02-07 2024-02-21 アルティオス ファーマ リミテッド 新規プロセス
WO2023125841A1 (zh) * 2021-12-29 2023-07-06 武汉人福创新药物研发中心有限公司 作为Polθ抑制剂的杂环化合物及其制备方法和用途
WO2023125918A1 (zh) * 2021-12-30 2023-07-06 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
TW202341998A (zh) * 2022-03-10 2023-11-01 大陸商四川海思科製藥有限公司 DNA聚合酶θ抑制劑及其用途
CN116730979A (zh) * 2022-03-11 2023-09-12 武汉人福创新药物研发中心有限公司 一种Polθ抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2698625T3 (es) * 2012-01-19 2019-02-05 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10760081B2 (en) 2015-10-07 2020-09-01 New York University Compositions and methods for enhancing CRISPR activity by POLQ inhibition
CN107556366A (zh) * 2016-06-30 2018-01-09 上海海和药物研究开发有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途

Also Published As

Publication number Publication date
CA3149119A1 (en) 2021-02-18
IL290415A (en) 2022-04-01
FI4010329T3 (fi) 2023-08-30
EP4010329B1 (en) 2023-06-07
LT4010329T (lt) 2023-09-11
EP4010329A1 (en) 2022-06-15
BR112022002496A2 (pt) 2022-04-26
AU2020327661A1 (en) 2022-02-24
JP2022544211A (ja) 2022-10-17
PT4010329T (pt) 2023-08-18
SI4010329T1 (sl) 2023-10-30
PL4010329T3 (pl) 2023-10-16
HUE063145T2 (hu) 2023-12-28
WO2021028670A1 (en) 2021-02-18
ES2952281T3 (es) 2023-10-30
TW202120486A (zh) 2021-06-01
US20220259174A1 (en) 2022-08-18
KR20220050148A (ko) 2022-04-22
EP4010329B9 (en) 2023-10-04
HRP20231037T1 (hr) 2023-12-08
RS64486B1 (sr) 2023-09-29
CN114846003A (zh) 2022-08-02
DK4010329T3 (da) 2023-09-04
ZA202201364B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2020014098A (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2018015094A (es) Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos.
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
GEP20146125B (en) Aminopyrimidines as syk inhibitors
AU2024202525A1 (en) Benzimidazolone derived inhibitors of BCL6
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2020007403A (es) Compuestos de tetrahidroisoquinolina.